Atorvastatin (Lipitor)

Clinical Summary

Atorvastatin is an HMG-CoA reductase inhibitor (statin) used for cholesterol lowering and cardiovascular risk reduction.

Documented on handwritten prescription as "Evitof" — likely brand name containing atorvastatin.

Newly documented from handwritten prescription dated 2026-05-04. Dosing schedule notation: 0-0-1 (2/d) — interpretation unclear. May mean "once daily in evening" or "twice daily" (contradictory notation).

Dosing History

[!info] Historical Context: Simvastatin → Atorvastatin Transition
In November 2022, Ishamma was on Simvastatin 10 mg at bedtime (low-intensity statin). By May 2026, she was on atorvastatin ("Evitof"). The switch occurred between Nov 2022 and May 2026 at an unknown date and for an unknown reason. Both simvastatin and atorvastatin are CYP3A4 substrates — neither choice mitigates the posaconazole interaction risk. Switch to pravastatin/rosuvastatin would be the safer approach.

Dose is not specified on handwritten Rx. Frequency notation is contradictory (0-0-1 suggests evening, but "2/d" suggests twice daily).

Indication

Presumed: Cardiovascular risk reduction in diabetes + dyslipidemia

Statins are indicated for:
1. Primary prevention in diabetes (age >40 with diabetes = automatic moderate-intensity statin indication per ACC/AHA guidelines)
2. LDL lowering in hyperlipidemia
3. Cardiovascular risk reduction (prior MI, stroke, PAD, etc. — not documented in Ishamma)

Ishamma's lipid status:
- Lipid panel Jul 2025: TC 152 mg/dL, LDL 80 mg/dL, HDL 50 mg/dL, TG 112 mg/dL — optimal (see Lipid Panel)
- Lipid panel Mar 2026: TC 159 mg/dL, LDL 90 mg/dL, HDL 47 mg/dL, TG 109 mg/dL — optimal

[!info] Lipids Already Optimal
Ishamma's LDL is already <100 mg/dL (optimal range for diabetes). Statin may be prescribed for:
1. Primary prevention (standard in diabetes age >40)
2. Maintaining optimal levels (was lipid panel optimal BECAUSE of statin, or despite no statin?)
3. Pleiotropic effects (anti-inflammatory, endothelial protection beyond lipid lowering)

Critical question: Was statin already being taken when lipid panels were drawn (Jul 2025, Mar 2026)? If yes, the optimal lipids are ON-statin. If no, the optimal lipids are OFF-statin, and statin may not be necessary.

Pharmacology

• Drug class: HMG-CoA reductase inhibitor (statin)
• Mechanism: Inhibits HMG-CoA reductase (rate-limiting enzyme in cholesterol synthesis) → reduced hepatic cholesterol → upregulation of LDL receptors → reduced plasma LDL
• Half-life: ~14 hours
• Metabolism: CYP3A4 (major pathway)
• Standard dosing:
• Low-intensity: 10 mg daily
• Moderate-intensity: 10–20 mg daily (most common in primary prevention)
• High-intensity: 40–80 mg daily (for secondary prevention or very high risk)

Monitoring

[!info] Hepatotoxicity Monitoring
Ishamma has had serial LFTs during AML treatment (Jan, Mar, Apr 2026) — all normal. No evidence of statin-induced hepatotoxicity (if statin was being taken during this period).

Drug Interactions

[!info] Posaconazole-Atorvastatin Interaction — RESOLVED (patient not taking atorvastatin)
Clinic note 2026-05-06 confirms patient is not taking atorvastatin. The previously flagged high-risk CYP3A4 interaction with posaconazole is therefore clinically moot.

For reference: Atorvastatin is metabolized by CYP3A4. If resumed, posaconazole would increase atorvastatin levels by 3–5 fold, with risk of myopathy and rhabdomyolysis. Before resuming any statin, consider switching to pravastatin or rosuvastatin (non-CYP3A4 metabolized) if posaconazole is still ongoing.

If atorvastatin is restarted in the future, close monitoring for myalgia and CK elevation would be required.

Other interactions:
- Gemfibrozil, fenofibrate: Increased myopathy risk (not applicable)
- Niacin: Increased myopathy risk (not applicable)
- Grapefruit juice: Increases atorvastatin levels (avoid)

Adverse Effects

• Myalgia (muscle pain, 5–10%) — increased risk with posaconazole interaction
• Myopathy / rhabdomyolysis (rare but serious) — increased risk with posaconazole
• Hepatotoxicity (ALT elevation >3× ULN in 0.5–2%) — monitor if symptomatic
• New-onset diabetes / worsened glucose control (small effect, ~0.1–0.2% HbA1c rise)
• Cognitive effects (memory impairment, confusion) — rare, reversible

Contraindications

• Active liver disease
• Pregnancy / breastfeeding
• Concurrent gemfibrozil (absolute contraindication due to rhabdomyolysis risk)

Related

• Lipid Panel — LDL 90 mg/dL (Mar 2026), already optimal
• Diabetes Mellitus — Primary prevention indication
• Posaconazole — CYP3A4 interaction; increased atorvastatin levels and myopathy risk
• Lft — All normal (Jan, Mar, Apr 2026)
• Myalgia / CK — Should be monitored (not yet documented)

[!info] Patient Non-Adherence — Confirmed 2026-05-06
Clinic note raw/clinic-notes/20260506_154838_note.md states: "she is not taking atarvostatin." Status changed active → discontinued. The posaconazole-atorvastatin CYP3A4 interaction is now clinically moot. No statin is currently active. Lipid monitoring gap: LDL was 90 mg/dL (Mar 2026, optimal), but no statin is providing ongoing cardiovascular protection.

Clinical gap: Cardiovascular risk in diabetes warrants statin therapy. A non-CYP3A4 statin (pravastatin, rosuvastatin) would avoid the posaconazole interaction and should be discussed with the prescriber.

Medication page created during ingest of 2026-05-04 handwritten prescription. Dose not specified. Frequency unclear. Status changed to discontinued 2026-05-06 — patient confirmed not taking.